Ulcer and gastritis

Endoscopy

Volumn 31, Issue 2, 1999, Pages 215-225

  Anand, B S ^a   Graham, D Y ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BISMUTH CITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RANITIDINE; TETRACYCLINE;

ADENOCARCINOMA; ANTIMICROBIAL THERAPY; ATROPHIC GASTRITIS; CANCER RISK; CLINICAL TRIAL; DUODENUM ULCER; GASTRITIS; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; LOWER ESOPHAGUS SPHINCTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CHILD; DUODENAL ULCER; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 0033037437     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-13672     Document Type: Review

References (50)

1. Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93: 574-8
2. Sprung DJ, Apter MN. What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? J Clin Gastroenterol 1998; 26: 60-3
3. Van der Hulst RW, Rauws EA, Koycu B, et al. Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis 1997; 176: 196-200
4. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-9
5. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs - comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92: 1322-5
6. Heikkinen M, Janatuinen E, Mayo K, et al. Usefulness of anti-Helicobacter pylori and anti-CagA antibodies in the selection of patients for gastroscopy. Am J Gastroenterol 1997; 92: 2225-9
7. Breuer T, Goodman KJ, Malaty HM, et al. How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol 1998; 93: 553-61
8. Breuer T, Sudhop T, Goodman KJ, et al. How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. Helicobacter 1998; 3: 1-8
9. Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 247-53
10. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus under 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease (abstract). Gastroenterology 1998; 114: A224
11. Graham DY, Yamaoka Y. H. pylori and CagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998; 3: 145-51
12. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113: 1983-91
13. Woo JS, el-Zimaity HM, Genta RM, et al. The best gastric site for obtaining a positive rapid urease test. Helicobacter 1996; 1: 256-9
14. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6
15. Yousfi MM, el-Zimaity HM, Cole RA, et al. Detection of Helicobacter pylori by rapid urease tests: is biopsy size a critical variable? Gastrointest Endosc 1996; 43: 222-4
16. Laine L, Chun D, Stein C, El-Beblawi I, et al. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation. Gastrointest Endosc 1996; 43: 49-53
17. Laine L, Estrada R, Lewin DN, Cohen H. The influence of warming on rapid urease test results: a prospective evaluation. Gastrointest Endosc 1996; 44: 429-32
18. Yousfi MM, el-Zimaity HM, Cole RA, et al. Does using a warmer influence the results of rapid urease testing for Helicobacter pylori? (letter). Gastrointest Enclose 1996; 43: 260-1
19. 2-receptor antagonists on test results. Scand J Gastroenterol 1998; 33: 364-9
20. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120-4
21. El-Zimaity HM, Al-Assi MT, Genta RM, Graham DY. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995; 90: 1962-4
22. Kokkola A, Rautelin H, Puolakkainen P, et al. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. J Clin Microbiol 1998; 36: 1808-10
23. Dale A, Thomas JE, Darboe MK, et al. Helicobacter pylori infection, gastric acid secretion, and infant growth. J Pediatr Gastroenterol Nutr 1998; 26: 393-7
24. Mata L. Diarrheal disease as a cause of malnutrition. Am J Trop Med Hyg 1992; 47: 16-27
25. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-42
26. McColl KE, El-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998; 42: 618-22
27. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9
28. Greenhalgh T. How to read a paper: the basics of evidence-based medicine. London BMJ Publishing Group 1997
29. Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double-blind placebo-controlled study. Ital J Gastroenterol Hepatol 1998; 30: 43-7
30. Graham DY. Famotidine to prevent peptic ulcer caused by NSAIDs (letter). N Engl J Med 1996; 335: 1322
31. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-9
32. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMMUM) Study Group. N Engl J Med 1998; 338: 727-34
33. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-50
34. Graham DY. High-dose famotidine for prevention of NSAID ulcers? (editorial). Gastroenterology 1997; 112: 2143-5
35. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817-22
36. Cuoco L, Cammarota G, Tursi A, et al. Disappearance of gastric mucosa-associated lymphoid tissue in coeliac patients after gluten withdrawal. Scand J Gastroenterol 1998; 33: 401-5
37. Feeley KM, Heneghan MA, Stevens FM, McCarthy CF. Lymphocytic gastritis and coeliac disease: evidence of a positive association. J Clin Pathol 1998; 51: 207-10
38. D'Inca R, Sturniolo G, Cassaro M, et al. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn's disease. Dig Dis Sci 1998; 43: 988-92
39. Fujii T, Iishi H, Tatsuta M, et al. Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial. Gastrointest Endosc 1998; 47: 382-7
40. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between CagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-90
41. Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol 1994; 25: 915-9
42. Graham DY. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Prev Med 1994; 23: 712-6
43. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31
44. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24
45. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664-8
46. Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori (letter). Lancet 1997; 350: 70-1
47. Blaser MJ. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet 1997; 349: 1020-2
48. Romero Y, Cameron AJ, Locke GR III, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113: 1449-56
49. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997; 26: 487-94
50. Cameron AJ. Barrett's esophagus: does the incidence of adenocarcinoma matter? (editorial). Am J Gastroenterol 1997; 92: 193-4